Active — Not RecruitingNot Applicable

New Vital Pulpotomy Medications in Primary Molars

Egypt48 participantsStarted 2023-05-01

Plain-language summary

Evaluate clinically and radiographically the effect of biodentine and hyaluronic acid (HA) versus formocresol (FC) as pulpotomy medications in primary molars.

Who can participate

Age range4 Years – 7 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Restorable mandibular primary molars with deep carious lesions.
✓. Absence of gingival swelling or sinus tract.
✓. Absence of spontaneous pain
✓. Absence of pain on percussion. B-Radiographic Criteria: Absence of
✓. Discontinuity of lamina dura
✓. Internal root resorption.
✓. External root resorption.
✓. inter-radicular or periapical bone destruction (radiolucency)

Exclusion criteria

✕. Excessive bleeding during pulp amputation.
✕. Non vital/necrotic teeth.
✕. Any sort of medical history contraindicating the pulp treatment.
✕. Teeth approximate exfoliation
✕. Patient's guardians are not intending to be part of the study.
✕. Retreatment of previously pulpotomy treated molar -

What they're measuring

clinically successful pulpotomy

Timeframe: 18 months

radiographically successful pulpotomy

Timeframe: 18 months

Trial details

NCT IDNCT05937100

SponsorMansoura University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-07-01

View on ClinicalTrials.gov More Carious Exposure of Pulp trials